NBIO News and Press, Nascent Biotech From 06/03/20

SAN DIEGO, CA / ACCESSWIRE / June 3, 2020 / Nascent Biotech, Inc (OTCQB:NBIO) (the "Company" or "Nascent") is pleased to provide a corporate update and summary with a recent interview the Company's CEO, Sean Carrick, presented on SNN Network. The complete interview may be seen on the SNN Net...

May 28, 2020 Palm Beach, FL – May 28, 2020 – Glioblastoma is a type of brain cancer. It’s the most common type of malignant brain tumor among adults. And it is usually very aggressive, which means it can grow fast and spread quickly. Glioblastoma multiforme is...

May 27, 2020 Palm Beach, FL – May 27, 2020 – Multiple industry reports project that the global G lioblastoma multiforme  (GBM) drugs market is expected to reach nearly $1.4 billion by 2025, expanding at a CAGR of 12.6% during the forecast period, driven by risin...

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc (OTCQB: NBIO) (the “Company” or “Nascent”) is pleased to announce that the Company will soon  begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma (GBM), the d...

SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, and Manhattan BioSolutions, Inc., a biotechnology company focused on the discovery...

SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc (OTCQB: NBIO). On April 22, 2020, Nascent Biotech Inc. (the “Company”) notified Triton Funds, LLC (“Triton”) that it was cancelling their Stock Purchase Agreement (the “SPA”) and ca...

April 22, 2020 Palm Beach, FL – April 22, 2020 – Scientists around the world are trying to go where no man has gone before… to develop a vaccine in less than 12-18 months… much less. The pressure is great but the collaboration s unprecedented. Anthony F...

SAN DIEGO, April 22, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc., (OTCQB: NBIO) (the “Company” or “Nascent”) a leading biotechnology company developing proprietary human Monoclonal Antibodies (mAbs) and immunotherapy for treatment of cancer, is pleased to pres...

SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- Nascent, Biotech, Inc., (OTCQB: NBIO ), a biotechnology company developing proprietary human Monoclonal Antibodies (mAbs) and immunotherapy for treatment of cancer, today announced that it will be presenting at the Planet MicroCap Showca...

NEW YORK, NY, April 09, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nascent Biotech, Inc. (OTCQB: NBIO) (the "Company"), a biotechnology company developing proprietary human Monoclonal Antibodies (mAbs) and immunotherapy for treatment of cancer, was recently featured in an article by...